Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay

Dekking, E; Velden, Vincent H.J. van der; Böttcher, Sebastian; Brüggemann, Monika; Sonneveld, Edwin; Koning-Goedheer, Anneke; Boeckx, Nancy; Lúcio, Paulo; Sędek, Łukasz; Szczepański, Tomasz; Kalina, Tomáš; Kovac, Martin; Evans, Paul; Hoogeveen, Patricia G.; Flores‐Montero, Juan; Órfão, Alberto; Comans-Bitter, W. M.; Staal, Frank J. T.; Dongen, Jacques J. M. van

doi:10.1016/j.beha.2010.09.010

Cited by 23 publications

(16 citation statements)

References 28 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20.4a ). The p210 transcript/protein is predominately involved in chronic myelogenous leukemia (CML) [ 17 ], the p190 transcript/ protein is most frequently associated with BCR-ABL1 -positive ALL, and patients with the p230 transcript/protein often demonstrate CML with prominent neutrophilic maturation and/or conspicuous thrombocytosis [ 7 ]. All BCR-ABL1 fusion proteins are permissive for oncogenesis.…”

Section: Detection Of Bcr-abl1 Mrna Transcriptmentioning

confidence: 99%

Genomic Applications in Hematologic Oncology

Fisher

Hill

2014

Genomic Applications in Pathology

View full text Add to dashboard Cite

Section: Detection Of Bcr-abl1 Mrna Transcriptmentioning

confidence: 99%

Genomic Applications in Hematologic Oncology

Fisher

Hill

2014

Genomic Applications in Pathology

View full text Add to dashboard Cite

“…This approach increases assay specificity since two antibodies must recognize the same molecule [80]. A microparticle proximity ligation assay requiring recognition of the target molecule by 3 antibodies detected VEGF, IL-8 and IL-6 in 5 μl samples of serum and whole blood [11].…”

Section: Micro and Nano Particle Based Approachesmentioning

confidence: 99%

“…Leukemia often results from the fusion of two normal proteins in the cell. Binding of antibody-conjugated beads to each of the two proteins in a leukemia-linked fusion protein and detection by flow cytometry enabled the detection of leukemic cells [80]. …”

Section: Micro and Nano Particle Based Approachesmentioning

confidence: 99%

Protein Analytical Assays for Diagnosing, Monitoring, and Choosing Treatment for Cancer Patients

Powers

Palecek

2012

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Cancer treatment is often hindered by inadequate methods for diagnosing the disease or insufficient predictive capacity regarding therapeutic efficacy. Targeted cancer treatments, including Bcr-Abl and EGFR kinase inhibitors, have increased survival for some cancer patients but are ineffective in other patients. In addition, many patients who initially respond to targeted inhibitor therapy develop resistance during the course of treatment. Molecular analysis of cancer cells has emerged as a means to tailor treatment to particular patients. While DNA analysis can provide important diagnostic information, protein analysis is particularly valuable because proteins are more direct mediators of normal and diseased cellular processes. In this review article, we discuss current and emerging protein assays for improving cancer treatment, including trends toward assay miniaturization and measurement of protein activity.

show abstract

“…This assay detects the fusion proteins in lysates of leukemic cells by use of a bead-bound catching antibody against one side of the fusion protein and a fluorochrome-conjugated detection antibody [141516]. …”

Section: Introductionmentioning

confidence: 99%

Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia

et al. 2017

View full text Add to dashboard Cite

BackgroundPhiladelphia chromosome, a hallmark of chronic myeloid leukemia (CML), plays a key role in disease pathogenesis. It reflects a balanced reciprocal translocation between long arms of chromosomes 9 and 22 involving BCR and ABL1 genes, respectively. An accurate and reliable detection of BCR-ABL fusion gene is necessary for the diagnosis and monitoring of CML. Previously, many technologies, most of which are laborious and time consuming, have been developed to detect BCR-ABL chimeric gene or chromosome.MethodsA new flow cytometric immunobead assay was used for detection of BCR-ABL fusion proteins and applicability, sensitivity, reliability, efficacy and rapidity of this method was evaluated.ResultsFrom February 2009 to January 2014, a total 648 CML patients were investigated for the status of BCR-ABL1 protein. Among them, 83 patients were enrolled for comparative study of BCR-ABL1 positivity by three routinely used procedures like karyotyping, and quantitative real time PCR (RT-PCR) as well as immunobead flow cytometry assay. BCR-ABL protein analysis was found consistent, more sensitive (17% greater sensitivity) and reliable than the conventional cytogenetics, as flow cytometry showed 95% concordance rate to RT-PCR.ConclusionBCR-ABL fusion protein assay using a new flow cytometric immunobead might be useful in the diagnosis and monitoring CML patients.

show abstract

Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay

Cited by 23 publications

References 28 publications

Genomic Applications in Hematologic Oncology

Genomic Applications in Hematologic Oncology

Protein Analytical Assays for Diagnosing, Monitoring, and Choosing Treatment for Cancer Patients

Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia

Contact Info

Product

Resources

About